Brain Arteriovenous MalformationsMAV-IRMNCT02896881
Interest of New MRI Sequences After Embolization of Brain Arteriovenous Malformations
An observational study of Brain Arteriovenous Malformations, run by Fondation Ophtalmologique Adolphe de Rothschild at 1 site in France.
Trial summary
In previous studies exploring specific sequences of MRI (susceptibility weighted imaging (SWI) and arterial spin labeling (ASL)), the investigators have shown the great sensibility of these MRI sequences to detect arteriovenous shunts, compared to angiography imaging (static or dynamic). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Brain Arteriovenous Malformations
- How many people
- 53 participants
- Where
- 1 siteFrance
- Study dates
- 1 Feb 2017to 3 Feb 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patient with brain Arteriovenous Malformations and embolization treatment scheduled.
Who may be able to join
- Patient ≥ 18 years old
- with brain Arteriovenous Malformations
- embolization treatment scheduled
Who cannot join
- patient's refusal to participate in the study
- contraindication to undergo MRI examination
- patient under legal protection
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Interest of New MRI Sequences After Embolization of Brain Arteriovenous Malformations (MAV-IRM)
In previous studies exploring specific sequences of MRI (susceptibility weighted imaging (SWI) and arterial spin labeling (ASL)), the investigators have shown the great sensibility of these MRI sequences to detect arteriovenous shunts, compared to angiography imaging (static or dynamic). This prospective study aims to compare multisequence MRI to brain arteriography imaging in patients undergoing brain arteriovenous malformations embolization.
Read the detailed description
Cerebral arteriovenous malformations are treated to eliminate the potential risk of haemorrhage. There are three possible treatment modalities: surgery, radiosurgery or embolisation. Complete exclusion of the arteriovenous malformation is a prerequisite for confirming that there is no residual risk of haemorrhage. After treatment, arteriography is the gold standard for confirming this exclusion. The absence of early opacification of the venous drainage is considered a sign of cure.
Several arteriographic aspects are possible after treatment by embolisation:
- Arteriography may be strictly normal (no abnormalities).
- The persistence of early venous opacification (presence of arterialised blood) indicates the persistence of a residual AVM.
- Other vascular anomalies without early venous drainage may be present: dysplastic vessels (irregular shape, "corkscrew" appearance) ; capillary blush in the embolisation bed (hyperaemia) ; other: slow flow, slow filling, or widening of afferent arteries.
Our previous studies exploring the use of specific MRI sequences, in magnetic susceptibility (SWI), arterial spin labelling (ASL) and angiography (static or dynamic) sequences, have enabled us to demonstrate the very high sensitivity of these sequences for detecting an arteriovenous shunt, whether native (when the AVM is discovered) or residual after treatment. We would like to carry out a prospective study to compare cerebral arteriography and MRI (multi-sequence) in patients treated by embolisation for cerebral arteriovenous malformation.
- Conditions
- Brain Arteriovenous Malformations
What is being measured
The primary outcome is the main question the study is designed to answer.
sensitivity of multisequence MRI to detect a residual arteriovenous malformation after embolization
Early opacification of a vein, possibly associated with the presence of abnormal vessels, will be sought, indicating a residual malformation. After interpretation of the MRI (angio-MRI with multi-sequences, magnetic susceptibility (SWI), arterial spin labelling (ASL) and static or dynamic angiography), the result will be coded dichotomously: (presence/absence of a residual malformation). The arteriography result will be coded in the same way. The sensitivity of the new MRI sequences for detecting a residual arteriovenous malformation after treatment by embolisation will thus be assessed, compared with arteriography (gold-standard).
Measured: within 3 months after embolization
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Sep 2016 (estimated)
- Study start1 Feb 2017
- Primary completion3 Feb 2025
- Study completion3 Feb 2025
Why it stopped: The study no longer recruits patients, and its scientific relevance to healthcare practice has become obsolete.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Brain Arteriovenous MalformationsStudies of the same condition, open and under way.
- More trials run by Fondation Ophtalmologique Adolphe de RothschildThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 53 participants (actual)
Sponsor and investigators
- Lead sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
- Sponsor type
- Research network
- Responsible party
- Sponsor
- Investigators
- Raphaël BLANC, MD, Principal investigator, Fondation Ophtalmologique Adolphe de Rothschild
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02896881
- Sponsor's protocol ID
- RBC_2016_7
- Acronym
- MAV-IRM
- Status last verified
- Jan 2026
- First submitted
- 7 Sep 2016
- Last updated
- 22 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Interest of New MRI Sequences After Embolization of Brain Arteriovenous Malformations (MAV-IRM)
- ClinicalTrials.gov ID
- NCT02896881
- Acronym / sponsor ID
- MAV-IRM / RBC_2016_7
- Conditions
- Brain Arteriovenous Malformations
- Study type
- Observational
- Recruitment status
- TerminatedReason stopped: The study no longer recruits patients, and its scientific relevance to healthcare practice has become obsolete.
- Enrolment
- 53 participants (actual)
- Lead sponsor
- Fondation Ophtalmologique Adolphe de RothschildResearch network
- Study start
- 1 Feb 2017 (actual)
- Primary completion
- 3 Feb 2025 (actual)
- Study completion
- 3 Feb 2025 (actual)
- First posted
- 12 Sep 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In previous studies exploring specific sequences of MRI (susceptibility weighted imaging (SWI) and arterial spin labeling (ASL)), the investigators have shown the great sensibility of these MRI sequences to detect arteriovenous shunts, compared to angiography imaging (static or dynamic). This prospective study aims to compare multisequence MRI to brain arteriography imaging in patients undergoing brain arteriovenous malformations embolization.
Detailed description
Cerebral arteriovenous malformations are treated to eliminate the potential risk of haemorrhage. There are three possible treatment modalities: surgery, radiosurgery or embolisation. Complete exclusion of the arteriovenous malformation is a prerequisite for confirming that there is no residual risk of haemorrhage. After treatment, arteriography is the gold standard for confirming this exclusion. The absence of early opacification of the venous drainage is considered a sign of cure.
Several arteriographic aspects are possible after treatment by embolisation:
- Arteriography may be strictly normal (no abnormalities).
- The persistence of early venous opacification (presence of arterialised blood) indicates the persistence of a residual AVM.
- Other vascular anomalies without early venous drainage may be present: dysplastic vessels (irregular shape, "corkscrew" appearance) ; capillary blush in the embolisation bed (hyperaemia) ; other: slow flow, slow filling, or widening of afferent arteries.
Our previous studies exploring the use of specific MRI sequences, in magnetic susceptibility (SWI), arterial spin labelling (ASL) and angiography (static or dynamic) sequences, have enabled us to demonstrate the very high sensitivity of these sequences for detecting an arteriovenous shunt, whether native (when the AVM is discovered) or residual after treatment. We would like to carry out a prospective study to compare cerebral arteriography and MRI (multi-sequence) in patients treated by embolisation for cerebral arteriovenous malformation.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patient with brain Arteriovenous Malformations and embolization treatment scheduled.
Key inclusion criteria (3 listed)
- Patient ≥ 18 years old
- with brain Arteriovenous Malformations
- embolization treatment scheduled
Key exclusion criteria (3 listed)
- patient's refusal to participate in the study
- contraindication to undergo MRI examination
- patient under legal protection
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
sensitivity of multisequence MRI to detect a residual arteriovenous malformation after embolization
Time frame: within 3 months after embolization
Early opacification of a vein, possibly associated with the presence of abnormal vessels, will be sought, indicating a residual malformation. After interpretation of the MRI (angio-MRI with multi-sequences, magnetic susceptibility (SWI), arterial spin labelling (ASL) and static or dynamic angiography), the result will be coded dichotomously: (presence/absence of a residual malformation). The arteriography result will be coded in the same way. The sensitivity of the new MRI sequences for detecting a residual arteriovenous malformation after treatment by embolisation will thus be assessed, compared with arteriography (gold-standard).
Results and safety
The study was stopped early (reason given: The study no longer recruits patients, and its scientific relevance to healthcare practice has become obsolete.). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jan 2026.
Related trials for Brain Arteriovenous Malformations
Not yet recruitingObservational study
Twenty-five Years of Advanced RadioTherapy at San Raffaele Hospital
Malignant Tumor, Benign Neoplasm
RecruitingPhase 2
UCSD Image-Guided Cognitive-Sparing Radiosurgery for Intracranial Lesions
Brain Metastases, Adult, Neurocognitive Function
Active, not recruitingObservational study
Florida Cerebrovascular Disease Biorepository and Genomics Center
Cerebrovascular Disease, Ischemic Stroke
RecruitingObservational study
Liquid Biopsies for the Detection of Somatic Mutations in bAVMs
Brain Arterial Disease
RecruitingObservational study
Rapid Evacuation and Access of Cerebral Hemorrhage Registry
Intracerebral Hemorrhage
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Raphaël BLANC, MD principal investigator
Fondation Ophtalmologique Adolphe de Rothschild
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Brain Arteriovenous Malformations, run by Fondation Ophtalmologique Adolphe de Rothschild at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 22 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: The study no longer recruits patients, and its scientific relevance to healthcare practice has become obsolete.). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
sensitivity of multisequence MRI to detect a residual arteriovenous malformation after embolization (time frame: within 3 months after embolization). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jan 2026.